



A CASE REPORT OF LAPAROSCOPIC REMOVAL OF PARAGANGLIOMA FROM POSTERIOR WALL OF URINARY BLADDER

General Surgery

**Dr.miteshkumar
Modi**

**Dr.amitkumar
Polara**

Dr.indira Khedkar Research Guide

ABSTRACT

A paraganglioma is a rare neuroendocrine neoplasm that may develop at various body sites including the head, neck, thorax and abdomen). Unlike other types of cancer, there is no test that determines benign from malignant tumors; long-term followup is therefore recommended for all individuals with paraganglioma. Approximately 50% of patients with recurrent disease experience distant metastasis. The five-year survival in the setting of metastatic disease is 40% to 45%.

KEYWORDS

INTRODUCTION

Tumors of chromaffin cells, derived from the embryonic neural crest, usually originate from the adrenal medulla and are designated as pheochromocytomas. However, 10% of these tumors occur at extra-adrenal sites and are known as paragangliomas.[1] Paraganglioma of the urinary bladder are extremely rare and are usually functional and symptomatic.[2] We are reporting here an almost silent paraganglioma of the urinary bladder that presented only with a single episode of pain in abdomen in adult male.


CASE REPORT

A 23-year-old man presented with a chronic pain in suprapubic region, that resolved spontaneously. Physical examination was unremarkable. ultrasound suggestive of well defined hypoechoic mass in posterior wall of bladder measuring 26*23*23 mm with internal vascularity. metastatic workup was negative. Urine cytology for malignant cells was negative while cystoscopy revealed a smooth, well-vascularized mass on the left lateral wall of the bladder submucosal growth with indentation in posterior bladder wall. CECT abdomen suggestive of submucosal lesion on posterior wall of bladder with indentation over mucosa.differential diagnosis carcinoid? Hemangioma? Paraganglioma?

Urinary vanillylmandelic acid was normal in range.patient planned for laparoscopic removal of tumor.During mobilization of tumor ,there is no significant change in blood pressure.

Ultrasonography showing 26*23 cm mass on right posterior lateral wall of bladder

Laparoscopic view of tumor:



Histological examination of the specimen showed presence of round to polygonal cells arranged in small nests or Zellballen, separated by highly vascularized fibrous septa. Individual cells had centrally located nuclei with clumped chromatin and moderately abundant fine granular cytoplasm and the occasional invasion into detrusor layer. These features were consistent with paraganglioma. Immunohistochemistry was strongly positive for synaptophysin and chromogranin, while negative for cytokeratin that further confirmed the diagnosis.

Photomicrograph showing tumor cells invading the deep muscle tissue of bladder

At 1-month postoperative, plasma metanephrines, and urinary vanillylmandelic acid, checked, which were normal and contrast enhanced computed tomography kidney ureter bladder suggested no residual tumor, invasion or evidence of metastasis. Patient is on regular 3 monthly follow-up with history, physical examination, plasma and urinary metanephrines and cystoscopy. Till 2 years of follow-up, there is no recurrence of tumor.

DISCUSSION

Paraganglioma of the urinary bladder is very rare and account for 0.06% of all bladder tumors and 6% of extra-adrenal pheochromocytomas. However, in the genitourinary tract, the urinary bladder is the most common site (79.2%), followed by the urethra (12.7%), pelvis (4.9%), and ureter (3.2%). These tumors originate from chromaffin tissue of the sympathetic nervous system associated with the urinary bladder wall and are most commonly situated at the dome or the trigone of the bladder and may be nonfunctional or functional. They remain usually benign, but 15–20% tumors may show malignant behavior. Bladder paraganglioma occur more frequently in women than in men, and clinical presentation occur mainly during the third decade of life.

In functional tumors, presenting symptoms are usually resulting from excessive catecholamine secretion. The patient typically suffers from hypertensive crises that may be accompanied by headache, palpitations, hot flushes, and sweating. Postmicturition hypotension and syncope is another common presentation. These crises are mainly provoked by micturition, overdistention of the bladder, defecation, sexual activity, ejaculation, or bladder instrumentation. **About 17% of bladder paragangliomas are hormonally nonfunctional and can be asymptomatic.** Painless hematuria is a common presenting complaint in about 60% of reported cases, though it is nonspecific for paraganglioma and can be a presenting feature of any bladder tumor. Both computed tomography (CT) scanning and magnetic resonance imaging are useful in the localization of both the primary tumor and any metastases however scanning with ¹³¹Iodine metaiodinebenzylguanidine (MIBG) has been shown to have a very high sensitivity and specificity for pheochromocytoma detection.[4] Functional imaging that specifically targets the catecholamine

synthesis, storage, and secretion pathway is helpful in patients with paraganglioma, especially after surgical removal or in the detection of metastasis. In symptomatic patients, functional assessments of plasma and/or urine catecholamine levels are crucial in the initial workup and in the follow-up afterward. Plasma metanephrines are more sensitive and specific than urinary metanephrines for these lesions.

On cystoscopy appearance of a yellow, submucosal tumor should raise the suspicion of a bladder paraganglioma. Tumor manipulation may release of catecholamines that leads to potentially lethal transient hypertension and should be biopsied or resected under appropriate alpha-adrenergic blockade (phenoxybenzamine or prazosin) and preoperative volume expansion that have been shown to significantly reduce peri-operative mortality and morbidity.] Fortunately, in our patient intraoperative hypertension has not occurred.

On histopathology, tumor cells are seen as large cells with abundant granular cytoplasm arranged in a Zellballen pattern and are surrounded by a fibrous network rich in blood vessels. Bladder paraganglioma can be confused histologically with urothelial carcinomas, especially the nested variant of urothelial carcinoma, and other tumors including bladder granular cell tumors, metastatic large cell neuroendocrine carcinoma and malignant melanoma. Presence of diffuse growth pattern, focal clear cells, necrosis, and muscularis propria invasion, with significant cautery artefact, and failure of pathologists to include it in their differential diagnosis may lead to their misdiagnosis as urothelial cancer. In these circumstances, immunohistochemical analysis helps in their differentiation where these tumors are positive for neuroendocrine markers, such as neuron-specific enolase, chromogranin and synaptophysin but negative for urothelial marker cytokeratin. The diagnosis of a malignant tumor is difficult and is often proved clinically through presence of metastases.

Surgery is the mainstay of the treatment that requires total excision. If diagnosed preoperatively, a partial cystectomy is preferred over transurethral resection as majority of these tumors extend in the deep layers of the detrusor muscle. Chance of recurrence is high following resection and should not be considered as evidence of malignancy. Total cystectomy is reserved for large lesions when bladder preservation is impossible or in the presence of lymph node metastasis. Bladder paraganglioma is a chemo-resistant and radioresistant tumor, though radiation and chemotherapy, either in the neoadjuvant or adjuvant setting, has been used in a few cases.

Because bladder paragangliomas are likely to recur and to metastasize, lifelong follow-up with appropriate history, annual measurement of plasma and urinary catecholamine levels and cystoscopy is essential. Imaging study (CT scan and 123 I-MIBG scintiscan) should be done to locate recurrence and metastasis sites if reappearance of symptoms or resurgence of catecholamines occurs.[2]

REFERENCES

1. Leestma JE, Price EB., Jr Paraganglioma of the urinary bladder. *Cancer*. 1971;28:1063-73. [PubMed]
2. Al-Zahrani AA. Recurrent urinary bladder paraganglioma. *Adv Urol*. 2010 912125. [PMC free article][PubMed]
3. Hanji AM, Rohan VS, Patel JJ, Tankshali RA. Pheochromocytoma of the urinary bladder: A rare cause of severe hypertension. *Saudi J Kidney Dis Transpl*. 2012;23:813-6. [PubMed]
4. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: A review. *Eur Urol*. 2003;44:672-81. [PubMed]
5. Sheps SG, Jiang NS, Klec GG, van Heerden JA. Recent developments in the diagnosis and treatment of pheochromocytoma. *Mayo Clin Proc*. 1990;65:88-95. [PubMed]
6. Chen CH, Boag AH, Beiko DT, Siemens DR, Froese A, Isotalo PA. Composite paraganglioma-ganglioneuroma of the urinary bladder: A rare neoplasm causing hemodynamic crisis at tumour resection. *Can Urol Assoc J*. 2009;3:E45-8. [PMC free article][PubMed]
7. Zhou M, Epstein JI, Young RH. Paraganglioma of the urinary bladder: A lesion that may be misdiagnosed as urothelial carcinoma in transurethral resection specimens. *Am J Surg Pathol*. 2004;28:94-100. [PubMed]
8. Ibuki N, Komura K, Koyama K, Inamoto T, Segawa N, Tanimoto K, et al. A pheochromocytoma of urinary bladder treated with neoadjuvant chemotherapy. *Hinyokika Kiyo*. 2009;55:765-8. [PubMed]
9. Zwahlen D, Fishman PN, Honey J, Milosevic M, Tannock I. Malignant pheochromocytoma of the urinary bladder. *Can J Urol*. 2007;14:3455-7. [PubMed]